Anton P. Porsteinsson

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Effect of Citalopram on Agitation in Alzheimer Disease

Anton P. Porsteinsson, Lea T. Drye, Bruce G. Pollock et al. · JAMA · 2014 · 551 citations · Full text

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

Reisa A. Sperling, Stephen Salloway, David J. Brooks et al. · The Lancet Neurology · 2012 · 497 citations · Full text

Alzheimer's Disease, Dementia, Retrospective Analysis +6

Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition

Jeffrey L. Cummings, Jacobo Mintzer, Henry Brodaty et al. · International Psychogeriatrics · 2014 · 337 citations · Full text

Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease

Eric Siemers, Joseph F. Quinn, Jeffrey Kaye et al. · Neurology · 2006 · 294 citations

Csf Abeta, Neurochemical Biomarkers, Pharmacotherapy +19